Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CheckMate-1533: subcutaneous nivolumab dosing regimens with ipilimumab and chemotherapy in untreated metastatic or recurrent NSCLC
2024-520108-25-00Phase 2Authorised
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 11
01
Overview
Phase 2, randomised, open-label trial of nivolumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Nivolumab subcutaneous pharmacokinetics during cycle 1 and Nivolumab subcutaneous trough concentration before cycle 7 day 1. Planned start Sep 2025; status: authorised.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-520108-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520108-25-00.